Effects of PPARγ Ligands on Vascular Tone

Author(s): Salvatore Salomone, Filippo Drago.

Journal Name: Current Molecular Pharmacology

Volume 5 , Issue 2 , 2012

Become EABM
Become Reviewer

Abstract:

Peroxisome Proliferator-Activated Receptor γ (PPARγ), originally described as a transcription factor for genes of carbohydrate and lipid metabolism, has been more recently studied in the context of cardiovascular pathophysiology. Here, we review the available data on PPARγ ligands as modulator of vascular tone. PPARγ ligands include: thiazolidinediones (used in the treatment of type 2 diabetes mellitus), glitazars (bind and activate both PPARγ and PPARα), and other experimental drugs (still in development) that exploit the chemistry of thiazolidinediones as a scaffold for PPARγ-independent pharmacological properties. In this review, we examine both short (mostly from in vitro data)- and long (mostly from in vivo data)-term effects of PPARγ ligands that extend from PPARγ-independent vascular effects to PPARγ-dependent gene expression. Because endothelium is a master regulator of vascular tone, we have attempted to differentiate between endothelium-dependent and endothelium-independent effects of PPARγ ligands. Based on available data, we conclude that PPARγ ligands appear to influence vascular tone in different experimental paradigms, most often in terms of vasodilatation (potentially increasing blood flow to some tissues). These effects on vascular tone, although potentially beneficial, must be weighed against specific cardiovascular warnings that may apply to some drugs, such as rosiglitazone.

Keywords: PPARγ, thiazolidinediones, Troglitazone, Rosiglitazone, Pioglitazone, Vascular tone

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 5
ISSUE: 2
Year: 2012
Page: [282 - 291]
Pages: 10
DOI: 10.2174/1874467211205020282
Price: $58

Article Metrics

PDF: 4